POHERDY
LaunchmAbpertuzumab-dpzb
BLAINTRAVENOUSINJECTABLE
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POHERDY (pertuzumab-dpzb) is a monoclonal antibody biosimilar approved for HER2-positive breast cancer, including metastatic disease. It targets HER2 receptor signaling to inhibit tumor cell proliferation and survival. This is a biosimilar to the reference product pertuzumab, expanding treatment access in HER2+ populations.
Launch
Early-stage biosimilar launch presents opportunity to establish market presence in competitive HER2+ space; team size will likely be modest initially, focused on payer access and oncology specialist penetration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on POHERDY positions you in oncology specialty pharma during a critical market access and launch phase. Roles emphasize payer negotiation, health economics, and rapid penetration in a crowded competitive space rather than novel drug development, making this ideal for commercial-minded professionals.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.